MADISON, N.J., Oct. 31 /PRNewswire-FirstCall/ -- Wyeth announced today that the jury in the cases of Lee Ann Brunson v. Wyeth, Colleen Rondas v. Wyeth and Lonnie Zimmerman v. Wyeth in the Philadelphia Court of Common Pleas found in favor of Wyeth in all three cases.
This is the second diet drug trial to go to verdict in Philadelphia this month. Of the ten plaintiffs who were originally included in those two trial groups, five plaintiffs voluntarily dismissed their cases before trial, four cases resulted in verdicts for Wyeth, and one case resulted in a verdict of $88,000 for the plaintiff. The plaintiffs in both trial groups were represented by the firms of Williams & Bailey and Blizzard, McCarthy & Nabers of Houston, Texas.
The trial began on October 18, 2005 before The Honorable Stephen Levin. The plaintiffs alleged heart valve injury from the use of the diet drug Pondimin, a drug once marketed by Wyeth.
Wyeth is one of the world’s largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing, and marketing of pharmaceuticals, vaccines, biotechnology products and nonprescription medicines that improve the quality of life for people worldwide. The Company’s major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.
Wyeth
CONTACT: Media: Douglas Petkus, +1-973-660-5218, or Investors: JustinVictoria, +1-973-660-5340, both of Wyeth
Web site: http://www.wyeth.com/